#gracecast

Vamos Falar Com Deus
Vamos Falar Com Deus
Abundant Grace Radio Show
Abundant Grace Radio Show
Dr. Geoffrey Oxnard on Managing Acquired Resistance to EGFR Inhibitor Therapy (and Probably Crizotinib, Too)
Dr. Geoffrey Oxnard on Managing Acquired Resistance to EGFR Inhibitor Therapy (and Probably Crizotinib, Too)
Dr. Rosalyn Juergens: What Novel Therapies Are You Most Optimistic About as Potential Lung Cancer Treatments in the Next Few Years?
Dr. Rosalyn Juergens: What Novel Therapies Are You Most Optimistic About as Potential Lung Cancer Treatments in the Next Few Years?
Dr. Monty Pal on the Current Best Practices for Early Stage Kidney Cancer
Dr. Monty Pal on the Current Best Practices for Early Stage Kidney Cancer
Dr. Lecia Sequist: Can We Bring The Advances in Targeted Therapy to Squamous NSCLC and Broader NSCLC Populations?
Dr. Lecia Sequist: Can We Bring The Advances in Targeted Therapy to Squamous NSCLC and Broader NSCLC Populations?
Dr. Lecia Sequist on Molecular Marker Testing in Advanced NSCLC in 2013: What, Who, and When?
Dr. Lecia Sequist on Molecular Marker Testing in Advanced NSCLC in 2013: What, Who, and When?
Dr. David Spigel: What are the most promising targeted therapy approaches in lung cancer for the next few years?
Dr. David Spigel: What are the most promising targeted therapy approaches in lung cancer for the next few years?
Dr. Pal on the Role of Interleukin-2 (IL-2) in Advanced Kidney Cancer Today
Dr. Pal on the Role of Interleukin-2 (IL-2) in Advanced Kidney Cancer Today
Dr. Sarah Goldberg: The Potential Value of a Treatment Break as an Alternative to Maintenance Therapy in Advanced NSCLC
Dr. Sarah Goldberg: The Potential Value of a Treatment Break as an Alternative to Maintenance Therapy in Advanced NSCLC
Dr. Sandler on Options for Maintenance Therapy: Switch, Continuation, or a Treatment Break?
Dr. Sandler on Options for Maintenance Therapy: Switch, Continuation, or a Treatment Break?
Dr. Alan Sandler: Is There a Danger that the Latest Advances in Molecular Testing Are Only Available in Limited Specialty Settings?
Dr. Alan Sandler: Is There a Danger that the Latest Advances in Molecular Testing Are Only Available in Limited Specialty Settings?
Dr. Harpole on Lung Surgery (Part 2): Advances in Surgical Techniques (video)
Dr. Harpole on Lung Surgery (Part 2): Advances in Surgical Techniques (video)
Drs. Ross Camidge and Corey Langer: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?
Drs. Ross Camidge and Corey Langer: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?
Dr. Monty Pal on Leading Options for First Line Treatment of Advanced Kidney Cancer
Dr. Monty Pal on Leading Options for First Line Treatment of Advanced Kidney Cancer
What is the Right Surgery for Early Stage Kidney Cancer?, by Dr. Monty Pal
What is the Right Surgery for Early Stage Kidney Cancer?, by Dr. Monty Pal
Dr. Heather Wakelee: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing
Dr. Heather Wakelee: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing
Do You Seek and Do You Use Molecular Marker Information in Patients with Early Stage NSCLC?
Do You Seek and Do You Use Molecular Marker Information in Patients with Early Stage NSCLC?
Dr. Lecia Sequist on Relevant Emerging Molecular Targets in Lung Cancer
Dr. Lecia Sequist on Relevant Emerging Molecular Targets in Lung Cancer
Dr. Heather Wakelee on the Most Promising New Agents and Pathways for Treating Lung Cancer in the Coming Years
Dr. Heather Wakelee on the Most Promising New Agents and Pathways for Treating Lung Cancer in the Coming Years
Dr. Matthew Katz: Introduction to Pancreatic Cancer (video)
Dr. Matthew Katz: Introduction to Pancreatic Cancer (video)
Dr. Sarah Goldberg on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer
Dr. Sarah Goldberg on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer
Dr. Matthew Katz: Introduction to Pancreatic Cancer (audio)
Dr. Matthew Katz: Introduction to Pancreatic Cancer (audio)
Dr. Lecia Sequist: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?
Dr. Lecia Sequist: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?
Drs. Ross Camidge and Corey Langer: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Drs. Ross Camidge and Corey Langer: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Dr. Greg Riely on "I just found out I have an EGFR mutation, and I'm in the middle of chemo. What now?"
Dr. Greg Riely on "I just found out I have an EGFR mutation, and I'm in the middle of chemo. What now?"
Dr. Ravi Salgia: How Do I Discuss the Side Effects of Targeted Therapies, as Compared with Chemotherapy?
Dr. Ravi Salgia: How Do I Discuss the Side Effects of Targeted Therapies, as Compared with Chemotherapy?
Dr. Sumanta (Monty) Pal: What is the Role of Surgery in the Treatment of Metastatic Kidney Cancer?
Dr. Sumanta (Monty) Pal: What is the Role of Surgery in the Treatment of Metastatic Kidney Cancer?
Dr. Lecia Sequist: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
Dr. Lecia Sequist: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
Managing Pancreatic Cancer: Systemic Therapy for Localized Prostate Cancer (audio)
Managing Pancreatic Cancer: Systemic Therapy for Localized Prostate Cancer (audio)
Dr. Karen Kelly on "My Approach to Maintenance Therapy for Advanced NSCLC"
Dr. Karen Kelly on "My Approach to Maintenance Therapy for Advanced NSCLC"
What is MyCancerGenome.org?
What is MyCancerGenome.org?
Dr. Phil Bonomi: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?
Dr. Phil Bonomi: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?
Dr. Phil Bonomi: Is Maintenance Therapy after First Line Chemotherapy a Mandate, An Option, or a Neither?
Dr. Phil Bonomi: Is Maintenance Therapy after First Line Chemotherapy a Mandate, An Option, or a Neither?
Dr. Ravi Salgia on Management Strategies for Acquired Resistance to Targeted Therapies, Single Focus or More Diffuse
Dr. Ravi Salgia on Management Strategies for Acquired Resistance to Targeted Therapies, Single Focus or More Diffuse
Dr. Sarah Goldberg: What Methods Do I Use to Obtain Samples for Molecular Testing?
Dr. Sarah Goldberg: What Methods Do I Use to Obtain Samples for Molecular Testing?
Dr. Larry Einhorn: How Can We Replicate the High Cure Rates We've Achieved for Testicular Cancer in a Wide Range of Cancers?
Dr. Larry Einhorn: How Can We Replicate the High Cure Rates We've Achieved for Testicular Cancer in a Wide Range of Cancers?
Dr. Matthew Katz: Defining Resectability of Pancreatic Cancer (video)
Dr. Matthew Katz: Defining Resectability of Pancreatic Cancer (video)
Dr. Karen Kelly: Do You Continue a Treatment Beyond 4-6 Cycles to Exhaust its Benefit?
Dr. Karen Kelly: Do You Continue a Treatment Beyond 4-6 Cycles to Exhaust its Benefit?
Dr. Larry Einhorn: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
Dr. Larry Einhorn: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
Dr. Geoffrey Oxnard: Are Patients or Payers Objecting to Repeat Biopsy?
Dr. Geoffrey Oxnard: Are Patients or Payers Objecting to Repeat Biopsy?
Dr. David Spigel: Which Lung Cancer Patients Should We Be Doing Molecular Marker Testing For, and Should We Do "Reflex Testing"?
Dr. David Spigel: Which Lung Cancer Patients Should We Be Doing Molecular Marker Testing For, and Should We Do "Reflex Testing"?
Dr. Sumanta (Monty) Pal: What Are the Main Types of Kidney Cancer and Are They Managed Differently?
Dr. Sumanta (Monty) Pal: What Are the Main Types of Kidney Cancer and Are They Managed Differently?
Dr. Larry Einhorn: What is Your Opinion of Patients and Caregivers Searching the Internet for Information?
Dr. Larry Einhorn: What is Your Opinion of Patients and Caregivers Searching the Internet for Information?
Dr. Larry Einhorn: What are the Biggest Challenges We Face in Delivering Effective Cancer Care in the Next Decade?
Dr. Larry Einhorn: What are the Biggest Challenges We Face in Delivering Effective Cancer Care in the Next Decade?
Dr. Harpole on Lung Surgery (Part 2): Advances in Surgical Techniques (audio)
Dr. Harpole on Lung Surgery (Part 2): Advances in Surgical Techniques (audio)
Dr. Greg Riely: How Should We Approach Acquired Resistance to Targeted Therapies in Advanced NSCLC?
Dr. Greg Riely: How Should We Approach Acquired Resistance to Targeted Therapies in Advanced NSCLC?
Dr. Karen Reckamp: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Dr. Karen Reckamp: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Dr. Ravi Salgia on "My Approach to Maintenance Therapy for Advanced NSCLC"
Dr. Ravi Salgia on "My Approach to Maintenance Therapy for Advanced NSCLC"
Dr. Sarah Goldberg on "I Just Found Out I Have an EGFR Mutation, and I'm in the Middle of Chemo. What Now?"
Dr. Sarah Goldberg on "I Just Found Out I Have an EGFR Mutation, and I'm in the Middle of Chemo. What Now?"
Sto caricando